{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:34:41Z","timestamp":1771554881397,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00280-023-04635-3","type":"journal-article","created":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T11:47:19Z","timestamp":1706183239000},"page":"439-453","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants"],"prefix":"10.1007","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4728-531X","authenticated-orcid":false,"given":"Romain","family":"Sechaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gholamreza","family":"Rahmanzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ovidiu","family":"Chiparus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopal Krishna","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Breitschaft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans D.","family":"Menssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,25]]},"reference":[{"key":"4635_CR1","unstructured":"EMA (2017) Rydapt. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rydapt. Accessed 25 Apr 2023"},{"key":"4635_CR2","unstructured":"FDA (2021) RYDAPT\u00ae (midostaurin) capsules, for oral use Initial US. Approval: 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/207997s008lbledt.pdf. Accessed 09 Sep 2023"},{"issue":"2","key":"4635_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1124\/dmd.117.078006","volume":"46","author":"H Gu","year":"2018","unstructured":"Gu H, Dutreix C, Rebello S, Ouatas T, Wang L, Chun DY, Einolf HJ, He H (2018) Simultaneous physiologically based pharmacokinetic (PBPK) modeling of parent and active metabolites to investigate complex CYP3A4 drug-drug interaction potential: a case example of midostaurin. Drug Metab Dispos 46(2):109\u2013121. https:\/\/doi.org\/10.1124\/dmd.117.078006","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"4635_CR4","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1124\/dmd.116.072744","volume":"45","author":"H He","year":"2017","unstructured":"He H, Tran P, Gu H, Tedesco V, Zhang J, Lin W, Gatlik E, Klein K, Heimbach T (2017) Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug. Drug Metab Dispos 45(5):540\u2013555. https:\/\/doi.org\/10.1124\/dmd.116.072744","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"4635_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S0736-4679(97)00022-X","volume":"15","author":"SP Nordt","year":"1997","unstructured":"Nordt SP, Clark RF (1997) Midazolam: a review of therapeutic uses and toxicity. J Emerg Med 15(3):357\u2013365. https:\/\/doi.org\/10.1016\/S0736-4679(97)00022-X","journal-title":"J Emerg Med"},{"key":"4635_CR6","unstructured":"FDA (2017) WELLBUTRIN\u00ae (bupropion hydrochloride) tablets, for oral use Initial US. Approval: 1985. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/018644s052lbl.pdf"},{"key":"4635_CR7","unstructured":"FDA (2011) ACTOS (pioglitazone hydrochloride) tablets for oral use Initial US. Approval: 1999 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021073s043s044lbl.pdf. Accessed 5 May 2023"},{"key":"4635_CR8","unstructured":"FDA (2020) In vitro drug interaction studies\u2014cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. https:\/\/www.fda.gov\/media\/134582\/download. Accessed 18 Jun 2023"},{"key":"4635_CR9","unstructured":"EMA (2012) EMA Guideline on the investigation of drug interactions. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf. Accessed 18 Jun 2023"},{"issue":"10","key":"4635_CR10","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40262-015-0283-1","volume":"54","author":"JA Gibbons","year":"2015","unstructured":"Gibbons JA, de Vries M, Krauwinkel W, Ohtsu Y, Noukens J, van der Walt JS, Mol R, Mordenti J, Ouatas T (2015) Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet 54(10):1057\u20131069. https:\/\/doi.org\/10.1007\/s40262-015-0283-1","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"4635_CR11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/clpt.2014.83","volume":"96","author":"M Bosilkovska","year":"2014","unstructured":"Bosilkovska M, Samer CF, D\u00e9glon J, Rebsamen M, Staub C, Dayer P, Walder B, Desmeules JA, Daali Y (2014) Geneva cocktail for cytochrome P450 and P-glycoprotein activity assessment using dried blood spots. Clin Pharmacol Ther 96(3):349\u2013359. https:\/\/doi.org\/10.1038\/clpt.2014.83","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"4635_CR12","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00280-013-2287-6","volume":"72","author":"C Dutreix","year":"2013","unstructured":"Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y (2013) Investigation into CYP3A4-mediated drug\u2013drug interactions on midostaurin in healthy volunteers. Cancer Chemother Pharmacol 72(6):1223\u20131234. https:\/\/doi.org\/10.1007\/s00280-013-2287-6","journal-title":"Cancer Chemother Pharmacol"},{"key":"4635_CR13","unstructured":"FDA (2020) Clinical drug interaction studies\u2014cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. https:\/\/www.fda.gov\/media\/134581\/download. Accessed 23 Jun 2023"},{"issue":"1","key":"4635_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00280-022-04448-w","volume":"90","author":"R Sechaud","year":"2022","unstructured":"Sechaud R, Sinclair K, Grosch K, Ouatas T, Pathak D (2022) Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML). Cancer Chemother Pharmacol 90(1):19\u201327. https:\/\/doi.org\/10.1007\/s00280-022-04448-w","journal-title":"Cancer Chemother Pharmacol"},{"key":"4635_CR15","unstructured":"Gu H, Sechaud R, Hanna I, Pelis R, Einolf H (manuscript in preparation) Physiologically based pharmacokinetic modeling of midostaurin and metabolites at steady state to bridge drug interaction scenarios in lieu of clinical trials"}],"updated-by":[{"DOI":"10.1007\/s00280-024-04657-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000}}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04635-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04635-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04635-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T17:02:19Z","timestamp":1713978139000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04635-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,25]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["4635"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04635-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00280-024-04657-5","asserted-by":"object"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,25]]},"assertion":[{"value":"20 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00280-024-04657-5","URL":"https:\/\/doi.org\/10.1007\/s00280-024-04657-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R Sechaud, G Rahmanzadeh, and H Menssen are employees of Novartis Pharma AG, Switzerland. H Gu, A Taylor, O Chiparus, are employees of Novartis Pharmaceuticals Corporation, USA. GK Sharma is an employee of Novartis Healthcare Pvt. Ltd., India. A Breitschaft is an employee of Parexel International GmbH, Germany.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Both the studies were performed in accordance with the ethical principles, which have their origin in the Declaration of Helsinki and are consistent with Good Clinical Practice and applicable regulatory requirements. All participants of the study provided written informed consent according to international standards. Both studies were conducted at the Early Phase Clinical Unit of PAREXEL International GmbH in Berlin, Germany. The study protocols were reviewed and approved by the State Office of Health and Social Affairs Ethics Committee of Berlin (Landesamt f\u00fcr Gesundheitund Soziales Ethik-Kommission des Landes Berlin) for PAREXEL International GmbH. Study 1 with CYP substrates and Study 2 with oral contraceptives were registered under EudraCT number: 2018-002786-19 and EudraCT number: 2018-002867-25, respectively, and both obtained a favorable opinion from the IEC. The study participants were informed about the study procedures, risks, and benefits of their participation. Informed consent was documented by the investigator.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}]}}